Rivaroxaban-Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF study.
The Executive Steering Committee, on behalf of the ROCKET AF Study Investigators a
American Heart Journal.
159(3):340-347e1, March 2010.
(Format: HTML, PDF)